-
Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced that the Ministry of Health, Labour and Welfare of Japan has approved Tecentriq (atezolizumab) for the treatment of unresectable alveolar soft part sarcoma. This marks the first approval of an immune…
-
Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development
•
Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris’ proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm. Deal Terms and…
-
Chugai Seeks Approval for Elevidys Gene Therapy in Japan, Targeting Duchenne Muscular Dystrophy
•
Chugai Pharmaceutical Co., Ltd. (TYO: 4519), a subsidiary of Roche, has submitted a product approval application in Japan for delandistrogene moxeparvovec, marketed globally as Elevidys, a gene therapy aimed at treating Duchenne muscular dystrophy (DMD). The therapy is specifically indicated for ambulatory boys aged 3 to 7 years with DMD…
-
Ping An Healthcare and Technology Partners with Chugai Pharmaceutical to Establish Angina Pectoris Center
•
Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also recognized as PingAn Good Doctor, has entered into a partnership with Japanese firm Chugai Pharmaceutical to jointly establish an angina pectoris center. This collaboration aims to integrate medical expertise with technological innovation to enhance coronary heart disease management. Advancing Coronary…
-
Supreme People’s Court Rules Against Chugai in China’s First Patent Linkage Case
•
China’s Supreme People’s Court has delivered its verdict in the nation’s first patent linkage dispute, ruling against Japan’s Chugai Pharmaceutical Co., Ltd and in favor of generic drugmaker Wenzhou Haihe Pharmaceutical Co., Ltd. The case, involving osteoporosis drug eldecalcitol, marks a milestone under China’s Drug Patent Early Dispute Resolution Mechanism,…
-
Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis
•
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an active Vitamin D3 derivative, in China. The drug, approved in December 2020 for treating osteoporosis in postmenopausal women, will be promoted by Chugai Pharma China Co., Ltd and Roche’s local unit. Drug ProfileEdirol, first approved…
